Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sizofiran
- Development stage
- Phase 1
- Lead developer
- Kaken Pharmaceutical
- Modality
- Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
Sizofiran is a soluble beta-D-glucan polysaccharide produced by the fungus Schizophyllum commune. It acts as an immunostimulant and biological response modifier, primarily used as an adjunct in cancer therapy. Sizofiran stimulates the immune system by increasing cytokine production, activating macrophages and Langerhans cells, and enhancing the activity of polymorphonuclear leukocytes (PML) and natural killer (NK) cells. It has been marketed for cervical cancer in South Korea and Japan, often used alongside radiation therapy. Sizofiran was developed by Kaken Pharmaceutical[2][3][4]. Its antitumor effects have been most notable in cervical cancer; it has also been investigated for other cancers such as head and neck cancer but was found ineffective against gastric cancer[3]. The drug is classified as a beta-glucan immunomodulator.
- Brand names
- sonifilansizofilan
- Other names
- schizophyllansizofiranumsonifiran
02
Targets
CLEC7A (Dectin-1)αMβ2 (Integrin αMβ2)
Beyond the preview
Go deeper on sizofiran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sizofiran.